2. Search Result
Search Result
Pathways Recommended: Neuronal Signaling JAK/STAT Signaling
Results for "

T-cell receptor signaling

" in MedChemExpress (MCE) Product Catalog:

43

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

6

Peptides

9

Inhibitory Antibodies

4

Natural
Products

1

Isotope-Labeled Compounds

3

Oligonucleotides

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-130254
    CSK-IN-1
    3 Publications Verification

    		 Src Inflammation/Immunology Cancer
    CSK-IN-1 (compound 13) is a potent, orally active c-terminal Src kinase (CSK) with IC50 values below 3 nM and 4 nM in CSK HTRF and Caliper assay, respectively. CSK-IN-1 shows the ability to increase T cell proliferation induced by T cell receptor signaling .
    CSK-IN-1
  • HY-P99315
    Ruplizumab

    BG 9588; Anti-Human CD40L Recombinant Antibody; Hu5c8

    		 TNF Receptor Inflammation/Immunology
    Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Ruplizumab
  • HY-P10102
    Kp7-6
    2 Publications Verification

    		 Apoptosis PERK NF-κB Caspase JNK Inflammation/Immunology Cancer
    Kp7-6 is a Fas mimetic peptide and also a Fas/FasL antagonist. Kp7-6 specifically binds to Fas and FasL, disrupts receptor complexes, and blocks downstream apoptosis signaling pathways. Kp7-6 inhibits the phosphorylation of ERK1-2, induces the phosphorylation of IκBα, and activates NF-κB. Kp7-6 inhibits the activation of caspase-8, caspase-3 and JNK, and suppresses human amylin-induced β-cell apoptosis. Kp7-6 inhibits FasL-induced lymphoid cytotoxicity and apoptosis. Kp7-6 reduces local tumor FasL expression, increases CD8 +Fas + T cell infiltration, and decreases tumor volume in pancreatic neuroendocrine tumor models. Kp7-6 prevents concanavalin A-induced liver injury in mice. Kp7-6 is applicable to research related to type 2 diabetes, concanavalin A-induced hepatitis and pancreatic neuroendocrine tumors .
    Kp7-6
  • HY-156659
    NC1

    		Phosphatase ERK Inflammation/Immunology
    NC1 is a selective non-competitive and allosteric lymphoid-specific tyrosine phosphatase (LYP) inhibitor, with a Ki value 4.3 μM. NC1 allosterically regulates LYP/PTPN22 activity by restricting WPD loop movement. NC1 inhibits LYP activity in lymphoid T cells and enhances T-cell receptor signaling. NC1 can be used for the research of autoimmune diseases .
    NC1
  • HY-P5005
    VIPhyb

    		CMV PD-1/PD-L1 Infection Inflammation/Immunology Cancer
    VIPhyb is a vasoactive intestinal polypeptide (VIP) receptor antagonist. VIPhyb can inhibit VIP signaling, increase T-cell immunity and downregulate PD1. VIPhyb can inhibit cancer cell proliferation. VIPhyb can reduce inflammatory cytokine expression. VIPhyb can enhance viral clearance. VIPhyb can be used for the researches of cancer, infection and inflammation and immunology, such as non-small cell lung cancer (NSCLC), cytomegalovirus infection and colitis .
    VIPhyb
  • HY-13660
    Mocravimod hydrochloride
    2 Publications Verification

    KRP-203

    		 LPL Receptor Reactive Oxygen Species (ROS) Akt GSK-3 JAK STAT Metabolic Disease Inflammation/Immunology Cancer
    Mocravimod (hydrochloride) is an orally active sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs. Mocravimod (hydrochloride) preferentially binds to S1PR1 over S1PR2 and S1PR3 in cardiomyocytes. Mocravimod (hydrochloride) significantly lowered the concentration of reactive oxygen species (ROS), prevented mitochondrial permeability transition pore opening, boosted mitochondrial membrane potential (MMP), and increased phosphorylation of AKT, EKR, GSK-3β, JAK2, and STAT3. Mocravimod (hydrochloride) retains T cell effector function. Mocravimod (hydrochloride) can be used for the study of acute myelogenous leukemia, diabetes and Myocardial Ischemia-Reperfusion Injury (MIRI) .
    Mocravimod hydrochloride
  • HY-109038
    Mocravimod
    2 Publications Verification

    KRP-203 free base

    		 LPL Receptor Reactive Oxygen Species (ROS) Mitochondrial Metabolism Akt GSK-3 JAK STAT Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Mocravimod (KRP-203 free base) is a sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs. Mocravimod preferentially binds to S1PR1 over S1PR2 and S1PR3 in cardiomyocytes. Mocravimod significantly lowered the concentration of reactive oxygen species (ROS), prevented mitochondrial permeability transition pore opening, boosted mitochondrial membrane potential (MMP), and increased phosphorylation of AKT, EKR, GSK-3β, JAK2, and STAT3. Mocravimod retains T cell effector function. Mocravimod can be used for the study of acute myelogenous leukemia, diabetes and Myocardial Ischemia-Reperfusion Injury (MIRI) .
    Mocravimod
  • HY-P991336
    Ordastobart

    INBRX-106; ES-102

    		 Orexin Receptor (OX Receptor) Inflammation/Immunology Cancer
    Ordastobart (INBRX-106; ES-102) is a hexavalent OX40 agonist antibody. Ordastobart enhances OX40 receptor clustering, signaling, and downstream activation, thereby increasing the proliferation and activation of CD4 + and CD8 + T cells in vitro and in vivo. Ordastobart exhibits anti-tumor effects and improves survival in mouse models of cancer. Ordastobart is indicated for research in cancers such as fibrosarcoma and colorectal cancer .
    Ordastobart
  • HY-P991201
    REGN-7257

    		Interleukin Related Inflammation/Immunology
    REGN-7257 is a humanized monoclonal antibody targeting IL2RG. REGN-7257 blocks the signal transduction induced by common gamma chain (γc) cytokines via the IL2RG chain of the γc cytokine receptor complex. REGN-7257 is applicable for research on immune-mediated diseases and T cell-mediated diseases . Its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003).
    REGN-7257
  • HY-N0910
    Notoginsenoside Ft1
    1 Publications Verification

    		 PI3K mTOR Akt Apoptosis p38 MAPK ERK Transmembrane Glycoprotein Glutathione Reductase (GR) Estrogen Receptor/ERR Calcium Channel Ferroptosis G protein-coupled Bile Acid Receptor 1 FXR Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 + T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca 2+ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y12 receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance .
    Notoginsenoside Ft1
  • HY-116330
    Hyperforin

    		Calcium Channel TRP Channel Neurological Disease Inflammation/Immunology
    Hyperforin is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin modulates Ca 2+ levels by activating Ca 2+-conducting non-selective canonical TRPC6 channels and triggers adipose tissue thermogenesis via the Dlat-AMPK signaling axis to suppress obesity. Hyperforin also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .
    Hyperforin
  • HY-P99266
    Zanolimumab

    Anti-Human CD4 Recombinant Antibody

    		 Transmembrane Glycoprotein Inflammation/Immunology Cancer
    Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma .
    Zanolimumab
  • HY-135892
    GNE-1858
    3 Publications Verification

    		 MAP4K Inflammation/Immunology
    GNE-1858 is a potent and ATP-competitive hematopoietic progenitor kinase-1 (HPK1) inhibitor, with IC50s of 1.9 nM, 1.9 nM, and 4.5 nM for wild-type and the active mimetic mutants HPK1-TSEE and HPK1-SA, respectively .
    GNE-1858
  • HY-P11288
    ANT308

    		PACAP Receptor Apoptosis Cancer
    ANT308 is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 significantly enhances the activation and proliferation of T cells. ANT308 inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 can be used for the studies of acute myeloid leukemia (AML) and uveal melanoma (UVM) .
    ANT308
  • HY-P11288A
    ANT308 TFA

    		PACAP Receptor Apoptosis Cancer
    ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 TFA significantly enhances the activation and proliferation of T cells. ANT308 TFA inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 TFA can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM) .
    ANT308 TFA
  • HY-149056
    GNE-6893

    		MAP4K Interleukin Related Cancer
    GNE-6893 is an orally active, selective HPK1 inhibitor with a Ki < 0.02 nM. GNE-6893 enhances T cell receptor signaling in primary human T cells. GNE-6893 increases IL2 production in stimulated primary human T cells. GNE-6893 can be used for the research of chronic refractory cancers .
    GNE-6893
  • HY-P11107
    RP-832c

    		Apoptosis TNF Receptor Inflammation/Immunology Cancer
    RP-832c is a synthetic analogue of host defense peptides (HDP), targeting the mannose receptor CD206 on the surface of M2 polarized macrophages (Kd = 3.5 μM). RP-832c binding to CD206 induces a significant conformational change in the receptor, activating signaling pathways that lead to rapid apoptosis and repolarization of CD206-positive M2 macrophages to an M1 phenotype. RP-832c treatment significantly reduces CD206 gene expression in M2 macrophages while transiently increasing expression of TNF-α, a marker for M1 macrophages. RP-832c is used for the studies of T-cell lymphoma (CTCL) and idiopathic pulmonary fibrosis (IPF) .
    RP-832c
  • HY-159643
    NDI-101150

    		MAP4K IFNAR Interleukin Related Inflammation/Immunology Cancer
    NDI-101150 is an orally active, potent and selective hematopoietic progenitor cell kinase 1 (HPK1) inhibitor with an IC50 of 0.7 nM. NDI-101150 blocks HPK1-mediated negative regulation of immune receptor signaling, inhibits immunosuppression of T cell activation, enhances antigen-specific antibody production and augments B-cell activation. NDI-101150 inhibits tumor growth in syngeneic tumor models, establishes durable antitumor immune memory, and synergizes with anti-PD1 to enhance exhausted T cell activity and drive tumor regressions. NDI-101150 can be used for the research of cancer, such as breast cancer and colon cancer .
    NDI-101150
  • HY-155847
    LYP-IN-3

    		Phosphatase PD-1/PD-L1 Inflammation/Immunology Cancer
    LYP-IN-3 is a selective, orally active and reversible lymphoid-tyrosine phosphatase (LYP) inhibitor (IC50 = 2.55 μM, Ki = 0.93 μM). D34 exhibits high selectivity of PTP1B, PTPN12, PTPN5 and SSH2. LYP-IN-3 regulates the T-cell receptor (TCR) signaling by specifically inhibiting LYP. LYP-IN-3 does not significantly inhibit MC38 cell viability; its anti-tumor effect stems from immune regulation. LYP-IN-3 can significantly upregulate PD-L1 or PD-1 expression in different immune cells. LYP-IN-3 facilitates T-cell infiltration and enhances T-cell functions. LYP-IN-3 synergizes with PD-L1 blockade can significantly improve colorectal tumor regression. LYP-IN-3 can be used for the study of colorectal cancer .
    LYP-IN-3
  • HY-139678
    SC13

    		FLAP Opioid Receptor Apoptosis STING Neurological Disease Cancer
    SC13 is an orally active, selective Flap structure-specific endonuclease 1 (FEN1) inhibitor and mu opioid receptor (MOR) activator. SC13 impairs DNA damage repair and induces apoptosis in cancer cells. SC13 activates cGAS-STING signaling, increases chemokine secretion, and promotes CAR-T cell infiltration at solid tumour sites. SC13 can be used for the research of solid tumours and pain .
    SC13
  • HY-153085
    CD19 CAR circRNA

    		CD19 Inflammation/Immunology Cancer
    CD19 CAR circRNA will express CD19 car protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.
    CD19 CAR circRNA
  • HY-E70833
    ITK Recombinant Human Active Protein Kinase

    		Itk Cancer
    ITK is the Tec family tyrosine kinase that has been implicated in T cell receptor (TCR) signaling. ITK Recombinant Human Active Protein Kinase is a recombinant ITK protein that can be used to study ITK-related functions .
    ITK Recombinant Human Active Protein Kinase
  • HY-13644
    Gusperimus

    15-Deoxyspergualin

    		 Others Others
    Gusperimus is a fully synthetic racemate that has a novel mechanism of action by binding to the intracellular heat shock protein hsp70 and interfering with intracellular signal transduction. This mechanism of action can enhance the effect of immunosuppressive therapy. Gusperimus can inhibit the differentiation of T cells into cytotoxic T cells, reduce the expression of IL-2 receptors on CD4 and CD8 cells, and inhibit IFN-γ-induced B cell maturation. In addition, when used with cyclosporine, tacrolimus or mycophenolate mofetil, Gusperimus can enhance the immunosuppressive effect and prevent allogeneic transplant rejection.
    Gusperimus
  • HY-168963
    PROTAC BTK Degrader-13

    		PROTACs Btk Itk p38 MAPK Inflammation/Immunology Cancer
    PROTAC BTK Degrader-13 (Compound 25) is the PROTAC degrader for BTK with a DC50 of 0.27 μM. PROTAC BTK Degrader-13 inhibits the activity of BTK with an IC50 of 0.44 μM, inhibits IL-2-induced T cell kinase (ITK) with an IC50 of 2.16 μM. PROTAC BTK Degrader-13 inhibits p38 MAPK signaling pathway, block the activation of the BCR (B cell receptor) signaling pathway . (Pink: ligand for target protein BTK ligand 15 (HY-168965); Black: linker (HY-Y0524); Blue: ligand for E3 ligase cereblon (HY-103596))
    PROTAC BTK Degrader-13
  • HY-149773S
    HPK1-IN-40-d2

    		MAP4K Inflammation/Immunology Cancer
    HPK1-IN-40 (compound 49) is a potent and selective HPK1 inhibitor with an IC50 of 0.9 nM. HPK1-IN-40 reinvigorates T-cell receptor (TCR) signaling, promoting T-cell function and cytokine production in T cells while having anti-cancer activity .
    HPK1-IN-40-d2
  • HY-P990205
    Anti-Mouse/Human KLRG-1 Antibody (2F1)

    		C-type Lectin-like Receptors (CTLRs) Inflammation/Immunology
    Anti-Mouse/Human KLRG-1 Antibody (2F1) is a Syrian hamster-derived IgG type antibody inhibitor, targeting to mouse/human KLRG-1. Anti-Mouse/Human KLRG-1 Antibody (2F1) neutralizes KLRG1. Anti-Mouse/Human KLRG-1 Antibody (2F1) reduces T-cell receptor signals and regulatory T-cell accumulation. Anti-Mouse/Human KLRG-1 Antibody (2F1) can be used for the researches of immunology .
    Anti-Mouse/Human KLRG-1 Antibody (2F1)
  • HY-173311
    Cbl-b-IN-28

    		E1/E2/E3 Enzyme Interleukin Related Inflammation/Immunology Cancer
    Cbl-b-IN-28 (Compound B2) is an orally active Cbl-b inhibitor. Cbl-b-IN-28 promotes the secretion of cytokines such as IL-2 and enhances the function of immune cells by regulating the phosphorylation levels of key proteins in the T-cell receptor signaling pathway. Cbl-b-IN-28 can be used in research in the field of cancer immunology .
    Cbl-b-IN-28
  • HY-174630
    Human IL18R1 mRNA

    		mRNA Inflammation/Immunology
    Human IL18R1 mRNA encodes the human interleukin 18 receptor 1 (IL18R1) protein, a cytokine receptor that belongs to the interleukin 1 receptor family. IL18R1 is essential for IL18 mediated signal transduction. IFN-alpha and IL12 are reported to induce the expression of this receptor in NK and T cells.
    Human IL18R1 mRNA
  • HY-P1432A
    K-(D-1-Nal)-FwLL-NH2 TFA

    		GHSR Cancer
    K-(D-1-Nal)-FwLL-NH2 TFA is a high affinity and potent ghrelin receptor inverse agonist (Ki values are 4.9 and 31 nM in COS7 and HEK293T cells, respectively). K-(D-1-Nal)-FwLL-NH2 blocks ghrelin receptor-mediated Gq- and G13-dependent signaling pathways.
    K-(D-1-Nal)-FwLL-NH2 TFA
  • HY-143423A
    (S)-MALT1-IN-5

    		MALT1 Inflammation/Immunology Cancer
    (S)-MALT1-IN-5 is a potent inhibitor of MALT1 protease. (S)-MALT1-IN-5 inhibits the activity of MALT1 is expected to be able to correct the enhancement of MALT1 activity due to abnormality of T cell receptor signal or B cell receptor signal, and cancer or inflammatory disease caused by MALT1 activity is expected. (S)-MALT1-IN-5 has the potential for the research of MALT1-related diseases (extracted from patent WO2020111087A1, compound 1) .
    (S)-MALT1-IN-5
  • HY-170948
    A2AR modulator-1

    		Adenosine Receptor Cancer
    A2AR modulator-1 (Compound 45) is a selective negative allosteric adenosine A2a receptor (A2aR) modulator with an IC50 value of 9 nM. A2AR modulator-1 reduces the affinity of endogenous adenosine for the receptor and inhibits cAMP signaling pathway activation. A2AR modulator-1 potently restores pCREB phosphorylation in CD4 + T cells, reversing immunosuppression in the tumor microenvironment, and shows potential to suppress tumor growth and metastasis in triple-negative breast cancer models .
    A2AR modulator-1
  • HY-N12537A
    (2R,3S)-PD-1/PD-L1-IN-38

    		Aryl Hydrocarbon Receptor PD-1/PD-L1 Cancer
    (2R,3S)-PD-1/PD-L1-IN-38 (Compound (±)-13e) is an orally active Ah receptor (AhR) antagonist with in vivo and in vitro anticancer activity. (2R,3S)-PD-1/PD-L1-IN-38 promotes the secretion of INF-γ by CD8 +T cells and inhibits the signal transduction of PD-1/PD-L1 .
    (2R,3S)-PD-1/PD-L1-IN-38
  • HY-162816
    PROTAC HPK1 Degrader-3

    		PROTACs MAP4K Cancer
    PROTAC HPK1 Degrader-3 (compound C3) is an orally effective PROTAC targeting HPK1 (DC50=21.26 nM). HPK1 is a negative regulator of T cell receptors, which can lead to T cell dysfunction after abnormal activation. PROTAC HPK1 Degrader-3 can inhibit SLP76 and NF-κB signaling pathways and inhibit MAPK signal transduction, and has anticancer activity and immune activation. PROTAC HPK1 Degrader-3 has a certain oral bioavailability and can be combined with PD-L1 antibody therapy to achieve a tumor growth inhibition rate of 65.58%. PROTAC HPK1 Degrader-3 is composed of E3 ligase ligand Thalidomide (HY-14658; blue part), PROTAC linker tert-Butyl 3-oxoazetidine-1-carboxylate (HY-40146; black part), and target protein ligand HPK1-IN-51 (HY-162842; red part); the activity control of the target protein ligand can be HPK1 ligand 1 (HY-162841) [1] .
    PROTAC HPK1 Degrader-3
  • HY-P991820
    Anti-Mouse CD45 Antibody (I3/2.3)

    		Phosphatase Inflammation/Immunology
    Anti-Mouse CD45 Antibody (I3/2.3) reacts with the mouse CD45. CD45 plays a key role in T-cell receptor (TCR) and B-cell receptor (BCR) signal transduction. Recommend Isotype Controls: Rat IgG2b kappa, Isotype Control (HY-P990682) .
    Anti-Mouse CD45 Antibody (I3/2.3)
  • HY-174517
    Human TNFRSF14 mRNA

    		mRNA Inflammation/Immunology
    Human TNFRSF14 mRNA encodes the human TNF receptor superfamily member 14 (TNFRSF14) protein, a member of the TNF receptor superfamily. TNFRSF14 functions in signal transduction pathways that activate inflammatory and inhibitory T-cell immune response. It binds herpes simplex virus (HSV) viral envelope glycoprotein D (gD), mediating its entry into cells.
    Human TNFRSF14 mRNA
  • HY-174621
    Human IL21R mRNA

    		mRNA Inflammation/Immunology
    Human IL21R mRNA encodes the human interleukin 21 receptor (IL21R) protein, a cytokine receptor for interleukin 21 (IL21). IL21R can transduce the growth promoting signal of IL21, and is important for the proliferation and differentiation of T cells, B cells, and natural killer (NK) cells.
    Human IL21R mRNA
  • HY-P992448
    RC98

    		PD-1/PD-L1 Cancer
    RC98 is a monoclonal antibody targeting programmed cell death ligand 1 (PD-L1) and acts as a selective PD-L1 inhibitor. RC98 binds specifically to human and cynomolgus monkey PD-L1. RC98 blocks the interaction between PD-L1 and its receptor PD-1 to reverse T-cell inactivation mediated by PD-1/PD-L1 signaling. RC98 enhances the cytotoxic T-lymphocyte-mediated anti-tumor immune response against PD-L1-expressing tumor cells. RC98 can be used for the research of tumor immunity and solid tumors .
    RC98
  • HY-182960
    KRP-203 monophosphate

    		LPL Receptor Drug Derivative Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    KRP-203 monophosphate is a monophosphate of KRP-203 (HY-13660). KRP-203 is an orally active sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs .
    KRP-203 monophosphate
  • HY-P992061
    Anti-Mouse CD3E Antibody (500A2)

    		CD3 Calcium Channel Inflammation/Immunology
    Anti-Mouse CD3E Antibody (500A2) is an antibody targeting mouse CD3ε, which specifically binds to the region on CD3ε adjacent to the T cell receptor binding site. Anti-Mouse CD3E Antibody (500A2) triggers functional signal transduction in immature T cells and activates naive T cells. When cross-linked, Anti-Mouse CD3E Antibody (500A2) induces a rapid, robust and transient increase in cytoplasmic calcium concentration, acting as a potent calcium flux inducer. Anti-Mouse CD3E Antibody (500A2) is suitable for multiple experimental techniques such as flow cytometry, immunoprecipitation and EMARS reactions. It can be used to detect CD3E expression on thymocytes, mature T lymphocytes and NK-T cells from different mouse strains, or to identify membrane cluster components of the TCR complex, and shows no cross-reactivity with rat leukocytes .
    Anti-Mouse CD3E Antibody (500A2)
  • HY-P992161
    REGN-10597

    		Interleukin Related PD-1/PD-L1 Inflammation/Immunology Cancer
    REGN-10597, composed of an anti-huPD-1-targeting antibody and IL2Ra-IL2 moiety, is a PD-1-dependent IL-2 agonist. REGN-10597 binds PD-1 to deliver masked native IL-2 to PD-1+ T cells, engaging trimeric IL-2 receptors to activate downstream signaling. REGN-10597 can be used for the research on melanoma, prostate cancer, colorectal cancer, and ovarian cancer .
    REGN-10597
  • HY-183539
    INCB191358

    		DGK Interleukin Related Cancer
    INCB191358 is a selective and orally active inhibitor of diacylglycerol kinase α/ζ/ι (DGKα/ζ/ι ) with IC50 values of 0.12, 0.36 and 0.36 nM. INCB191358 induces antigen-dependent T-cell activation, induces IL-2 production and enhances antitumor efficacy in combination with PD-1 blockade. INCB191358 can be used for the research of cancer, such as colon carcinoma .
    INCB191358
  • HY-126675G
    AS2863619

    		CDK TGF-beta/Smad Apoptosis Inflammation/Immunology
    AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 + T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .
    AS2863619
  • HY-W097625R
    6-Methoxyflavone (Standard)

    		Toll-like Receptor (TLR) MyD88 p38 MAPK NF-κB Heme Oxygenase (HO) Reference Standards PERK Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    6-Methoxyflavone (Standard) is the analytical standard of 6-Methoxyflavone (HY-W097625). This product is intended for research and analytical applications. 6-Methoxyflavone is an orally active methoxyflavone. 6-Methoxyflavone suppresses neuroinflammation in microglia through the inhibition of TLR4/MyD88/p38 MAPK/NF-κB dependent pathways and the activation of HO-1/NQO-1 signaling. 6-Methoxyflavone induces S-phase arrest through the CCNA2/CDK2/p21CIP1 signaling pathway and activates the PERK/EIF2a/ATF4/CHOP pathway in HeLa cells. 6-Methoxyflavone acts as a Flumazenil (HY-B0009)-insensitive positive allosteric modulator at human recombinant α1β2γ2L and α2β2γ2L GABAα receptors. 6-Methoxyflavone inhibits NFAT Translocation into the nucleus and suppresses T cell activation. 6-Methoxyflavone partially restores chronic ethanol-induced behavioral deficits in mice. 6-Methoxyflavone antagonizes chronic constriction injury and diabetes associated neuropathic nociception expression. 6-Methoxyflavone can be used for the study of cancer, inflammation and neurological diseases .
    6-Methoxyflavone (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: